@article{0080211d5d9840c8a3e2b652d4789685,
title = "Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study",
keywords = "crizanlizumab, monoclonal antibody, sickle cell disease, vaso-occlusive crisis",
author = "Liles, {Darla K.} and Shah, {Nirmish R.} and Brigid Scullin and Gordeuk, {Victor R.} and Smith, {Wally R.} and Julie Kanter and Achebe, {Maureen M.} and Ralph Boccia and Crary, {Shelley E.} and Kraft, {Walter K.} and Natasha Archer and Vince Cataldo and Hardesty, {Brandon M.} and Modupe Idowu and Desai, {Payal C.} and Alan Ikeda and Geetha Puthenveetil and Hassell, {Kathryn L.} and Sharada Sarnaik and Abdullah Kutlar",
note = "Funding Information: Darla K. Liles has no conflicts to disclose. Nirmish R. Shah, reports consultancy fees and research funding from Novartis Pharmaceuticals Corporation and Global Blood Therapeutics; consultancy fees at CSL Behring and bluebird bio; speaker{\textquoteright}s bureau participation at Global Blood Therapeutics and Novartis Pharmaceuticals Corporation, outside of the submitted work. Brigid Scullin, reports honoraria from PHAR, LLC, and Novartis Pharmaceuticals Corporation, outside of the submitted work. Victor R. Gordeuk, reports grant support from Novartis Pharmaceuticals Corporation during conduct of the study; grant support from Global Blood Therapeutics, Imara, Inc., Takeda, Ironwood, Incyte, CSL Behring, and Pfizer; consultancy fees from CSL Behring, Forma Therapeutics, and Novartis Pharmaceuticals Corporation, outside of the submitted work. Wally R. Smith, reports research funding from consultancy fees from National Heart Lung and Blood institute, Novartis Pharmaceuticals Corporation, Patient‐Centered Outcomes Research Institute, and the United States Department of Health and Human Services/Health Resources and Services Administration, Pfizer Inc., Novartis Pharmaceuticals Corporation, Emmaus Medical, Inc., Imara Inc., and Shire; consultancy fees from Global Blood Therapeutics, Emmaus Medical, Inc., Pfizer Inc., and Novartis Pharmaceuticals Corporation, outside of the submitted work. Julie Kanter, reports funding from Novartis Pharmaceuticals Corporation during the conduct of the study, and honoraria from Novartis Pharmaceuticals Corporation, outside of the submitted work. Maureen M. Achebe has no conflicts to disclose. Ralph Boccia has no conflicts to disclose. Shelley E. Crary has no conflicts to disclose. Walter K. Kraft, reports grant support from Novartis Pharmaceuticals Corporation during the conduct of the study. Natasha Archer, reports grant support from Novartis Pharmaceuticals Corporation during the conduct of the study; grant support from Global Blood Therapeutics and from the American Society of Hematology/Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Award, outside of the submitted work. Vince Cataldo has no conflicts to disclose. Brandon M. Hardesty, reports fees for research from Global Blood Therapeutics and Novartis Pharmaceuticals Corporation, outside the submitted work. Modupe Idowu, reports grant support from UT Health McGovern Medical School, Houston, Texas, outside of the submitted work. Payal C. Desai, reports grant support from Selexys during the conduct of the study. Alan Ikeda has no conflicts to disclose. Geetha Puthenveetil has no conflicts to disclose. Kathryn L. Hassell, reports fees from Selexys and Novartis Pharmaceuticals Corporation during the conduct of the study; fees from Pfizer Inc., outside of the submitted work. Sharada Sarnaik has no conflicts to disclose. Abdullah Kutlar, reports consultancy fees, during the conduct of the study, and personal fees for participation in clinical trials from Novartis Pharmaceuticals Corporation; personal fees for participation in clinical trials and speaker program from Global Blood Therapeutics; honoraria from Blueprint Research Group, Saudi Society of Blood and Marrow Transplantation, MUH Life Sciences, and Vindico Medical Education; personal fees (DSMB membership) for bluebird bio, Inc. and Micelle BioPharma, Inc., outside of the submitted work.",
year = "2021",
month = nov,
doi = "10.1111/bjh.17739",
language = "English",
volume = "195",
pages = "e150--e153",
journal = "British Journal of Haematology",
issn = "0007-1048",
number = "4",
}